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Machado-Joseph disease (MJD/SCA3) is the most common form of dominantly inherited ataxia worldwide. The 
disorder is caused by an expanded CAG repeat in the ATXN3 gene. Past studies have revealed that the length of 
the expansion partly explains the disease age at onset (AO) variability of MJD, which is confirmed in this study 
(Pearson’s correlation coefficient R2 = 0.62). Using a total of 786 MJD patients from five different geographical 
origins, a genome-wide association study (GWAS) was conducted to identify additional AO modifying factors that 
could explain some of the residual AO variability. We identified nine suggestively associated loci (P < 1 × 10−5). 
These loci were enriched for genes involved in vesicle transport, olfactory signaling, and synaptic pathways. 
Furthermore, associations between AO and the TRIM29 and RAG genes suggests that DNA repair mechanisms 
might be implicated in MJD pathogenesis. Our study demonstrates the existence of several additional genetic 
factors, along with CAG expansion, that may lead to a better understanding of the genotype-phenotype 
correlation in MJD. 
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INTRODUCTION 
 
Machado-Joseph disease, also known as spinocerebellar 
ataxia type 3 (MJD/SCA3), is an autosomal dominant 
neurodegenerative disorder that is characterized by 
progressive cerebellar ataxia and pyramidal signs, which 
can be associated with a complex clinical picture and 
includes extrapyramidal signs or amyotrophy [1, 2]. MJD 
is caused by an abnormal CAG trinucleotide repeat 
expansion in exon 10 of the ataxin-3 gene (ATXN3), 
located at 14q32.1. Deleterious expansions (CAGexp) 
consensually contain 61 to 87 CAG repeats, whereas wild 
type alleles (CAGnor) range from 12 to 44 [2]. 
 
As with other diseases caused by repeat expansions, 
such as Huntington’s disease (HD) and other spino-
cerebellar ataxias, there is an inverse correlation 
between expanded repeat size and the age at which 
pathogenesis leads to disease onset [3]. Depending on 
the cohort structure, the size of the repeat expansion 
explains 55 to 70% of the age at onset (AO) variability 
in MJD, suggesting the existence of additional 
modifying factors [3, 4]. Although several genetic 
factors have been proposed as modifiers, such as CAG 
repeat size of normal ATXN3 (SCA3), HTT (HD), 
ATXN2 (SCA2) and ATN1 (DRPLA) alleles, APOE 
status, and expression level of HSP40 [4–6], these were 
not replicated by subsequent studies [7, 8]. Since CAG 
tract profile and allelic frequencies of the potential 
modifier loci can have unique characteristics in 
different populations, large collaborative studies are 
required to identify genetic modifiers in MJD, as well as 
replicate the findings of such studies [8]. 
 
Previously, Genetic Modifiers of Huntington’s Disease 
(GeM-HD) Consortium carried out a GWA approach of 
HD individuals to reveal genetic modifiers of AO in HD 
[9, 10]. A total of eleven [9] and fourteen loci [10] were 
found to be associated with residual age at HD onset. In 
the present study, we performed the first GWAS to 
identify some possible genetic modifiers of AO in MJD. 
First, we assessed the relationship between AO and size 
of the expanded (CAGexp) and normal (CAGnor) alleles, 
biological sex and geographical origin. Next, we 
determined a residual AO for each subject, which is the 
difference between the measured AO and the 
predicted/estimated AO from expanded CAG repeat 
size alone. Using the residuals as a quantitative 
phenotype for a GWAS, we looked for genetic factors 




The inverse correlation between CAGexp and age at 
onset 
 
In the first phase of the study, the expanded ATXN3-CAG 
repeat lengths of 786 MJD patients were assessed. The 
mean (SD) CAGexp size were Australia: 68.2 (±3.3), 
Brazil: 74.3 (3.9), Germany: 72.9 (±3.6), North America: 
73 (±4.3) and Portugal: 72 (±4.0). Next, the relationship 
between AO and CAGexp size, CAGnor size, sex and 
ethnicity was examined (Supplementary Table 1). The 
previously observed negative correlation between ATXN3 
CAGexp size and AO [3] was confirmed (Pearson’s 
correlation coefficient R2 = 0.62) (Figure 1). The CAGnor 
size (P = 0.39), sex (P = 0.02) and geographic origin (P 
[Brazil] = 0.38, P [Germany] = 0.38, P [North America] = 
0.33, P [Portugal] = 0.29) were not significant and their 
addition had little contribution to the model (ΔR2 = 
0.0072). Residual AO for each sample was calculated and 
used as a quantitative phenotype to identify the modifiers 
of AO. The distribution of residual AO was close a 




Figure 1. The inverse correlation between CAGexp and AO (left) and the distribution of residual AO (right) observed in our 
MJD cohort. 
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Genome-wide association study 
 
After post-imputation quality assessments, a total of 
700 individuals with genotyping information for 
6,716,580 variants remained for GWAS. The 
Manhattan plots are shown in Figure 2. The genomic 
inflation factor was close to one (λ = 0.98), indicating 
the p-values were not inflated. Genome-wide 
suggestive associations (P < 1 × 10−5) with 204 
variants across 9 loci were identified (Supplementary 
Table 3). The most significantly associated SNP at 
each locus are shown in Table 1. Positional gene 
mapping aligned SNPs to 17 genes by their genomic 
location. Fourteen of the 204 variants had a Combined 
Annotation Dependent Depletion (CADD)-PHRED 
score higher than the suggested threshold for 
deleterious SNPs (12.37), arguing the given loci have 
a functional role [11].  
 
Interaction analysis between CAGexp, sex and SNP 
genotype 
 
To assess a possible interaction between CAGexp size 
and the variants identified, each of the nine variants was 
added to the initial linear regression, modelling AO as a 
function of CAGexp size, SNP, sex, the first three 
principal components, CAGnor size, interactions of 
SNP:CAGexp and SNP:sex. Association of each 
independent SNP with AO revealed nominally 
significant p-values (P [rs7480166] = 8.42 × 10−6, P 
[rs62171220] = 6.33 × 10−3, P [rs2067390] = 4.51 × 
10−5, P [rs144891322] = 1.14 × 10−5, P [rs11529293] = 
1.62 × 10−5, P [rs585809] = 2.91 × 10−5, P [rs72660056] 
= 1.66 × 10−3, P [rs11857349] = 8.21 × 10−6, P 
[rs8141510] = 1.33 × 10−3). With the addition of the 
identified variants to the model, correlation coefficient 
R2 increased to 0.71 (ΔR2 = 0.082). Among the nine 
variants, only rs585809 (mapped to TRIM29) had a 
significant interaction with CAGexp (P = 0.01), 
suggesting that rs585809 might modulate AO through 
this epistatic interaction on CAGexp. The addition of 
SNP:sex interaction had little contribution to the model 
(ΔR2 = 0.005). 
 
Association of HD-AO modifier variants in MJD 
 
Association of previously identified HD-AO modifier 
loci in MJD were assessed. Among the 25 HD-AO 
modifier variants in 17 loci, a total of 18 variants 
(MAF > 0.02) in 12 loci were tested in this study 
(Supplementary Table 4). None of these HD-AO 
modifiers reached the genome-wide suggestive 
threshold. However, two variants rs144287831 (P = 
0.02, effect size = - 0.98) and rs1799977 (P = 0.02, 
effect size = - 0.98) in the MLH1 locus were found to 
be nominally associated with a later AO in MJD. 
 
Pathway and gene-set enrichment analysis 
 
A gene-set enrichment and pathway analysis was 
conducted using i-GSEA4GWAS v2 [12]. Various 
approaches and algorithms are currently in use to 
conduct similar analyses. To be able to make better 
comparisons with other studies that may use different 
approaches, we performed a secondary gene-set 
enrichment and pathway analysis using the VEGAS2 
[13] and PASCAL [14] software (Supplementary Tables 




Figure 2. Manhattan plot of the GWAS for residual AO of MJD. Imputed using the HRC panel, 6,716,580 variants that passed QC are 
included in the plot. The x-axis shows the physical position along the genome. The y-axis shows the −log10(p-value) for association. The red 
line indicates the level of genome-wide suggestive association (Px10−5). 
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Table 1. Suggestive loci associated with residual age at onset in MJD. Chr: chromosome, MAF: minor allele 
















rs62171220 2 137802855 THSD7B G C 0.13 0.11 2.71 4.45 × 10−6 
rs2067390 2 191209028 HIBCH, INPP1 A T 0.04 0.06 4.74 6.39 × 10−6 
rs144891322 5 85135387 RPL5P17, C T 0.02 0.007 6.10 5.18 × 10−6 
rs11529293 11 36855388 
C11orf74, RAG1, 
RAG2 
T C 0.14 0.26 -2.71 3.30 × 10−6 
rs7480166 11 42984753 HNRNPKP3 A G 0.40 0.40 -1.86 4.17 × 10−6 
rs585809 11 119949979 TRIM29 T C 0.06 0.17 -3.76 9.50 × 10−6 
rs72660056 13 113507543 ATP11A A G 0.08 0.05 -3.29 3.94 × 10−6 
rs11857349 15 99924857 
TTC23, SYNM, 
LRRC28 
G A 0.04 0.02 -4.58 3.43 × 10−6 
rs8141510 22 42821185 
NFAM1, CYP2D6, 
NAGA, NDUFA6 
C T 0.43 0.49 1.83 3.94 × 10−6 
 
Table 2. Pathways significant after multiple-correction (q < 5 x 10-2) in the primary GSEA analysis and replicated using 
at least one of the secondary gene-set enrichment algorithms. NA means that the pathway was not enriched by at 












GO:0030133 transport vesicle < 1.0 x 10-3 8.20 x 10-3 6.15 x 10-40 4.46 x 10-1 6.70 x 10-3 





< 1.0 x 10-3 8.80 x 10-3 1.10 x 10-27 7.71 x 10-1 2.51 x 10-4 
GO:0044456 synapse part < 1.0 x 10-3 9.30 x 10-3 1.25 x 10-182 < 1.0 x 10-6 < 1.0 x 10-7 
R-HSA:74217 purine salvage  < 1.0 x 10-3 1.06 x 10-2 1.06 x 10-2 2.15 x 10-1 6.48 x 10-3 




< 1.0 x 10-3 1.50 x 10-2 1.50 x 10-2 3.41 x 10-1 1.24 x 10-2 








< 1.0 x 10-3 2.26 x 10-2 2.26 x 10-2 1.30 x 10-4 2.30 x 10-5 
GO:0030140 
trans Golgi network 
transport vesicle 
< 1.0 x 10-3 2.36 x 10-2 2.36 x 10-2 2.80 x 10-2 1.28 x 10-1 
GO:0009725 
response to hormone 
stimulus 
< 1.0 x 10-3 2.73 x 10-2 2.73 x 10-2 1.32 x 10-1 1.30 x 10-4 
GO:0030425 Dendrite < 1.0 x 10-3 3.86 x 10-2 3.86 x 10-2 < 1.0 x 10-6 < 1.0 x 10-7 
 
purposes in our own study. A total of 13 
overrepresented pathways were found, after FDR-
multiple testing correction (q-value < 0.05) in the 
primary GSEA analysis and replicated using at least 
one of the secondary gene-set enrichment algorithms 
(Table 2). Overall, the most significantly enriched 
gene-sets and pathways were vesicle transport, 
olfactory signaling, and synaptic pathways. 
Visualization and clustering of pathways are shown in 
Figure 3.  
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DISCUSSION 
 
Using five cohorts from different geographical origins, 
we performed the first GWAS to examine the presence 
of genetic factors that could modify AO in MJD. We 
identified a total of nine loci that were potentially 
associated with either an earlier or later AO. 
Concomitantly, we confirmed the previously observed 
negative correlation between CAGexp and AO [3]. It was 
shown previously that normal ATXN3 allele (CAGnor) 
had a significant influence on AO of MJD [15]; 
however, several studies did not replicate this effect [6, 
8]. Indeed, we did not observe an association between 
CAGnor and AO. However, it had little contribution to 
our model, with a minor difference in the correlation 
coefficient (ΔR2 = 0.0012).  
 
In our GWAS, the strongest signal is for the rs11529293 
variant (P = 3.30 × 10-6) within the C11orf72 and RAG 
loci at 11p12. Within this locus, two RAG genes, 
recombination-activating genes RAG1 and RAG2, were 
shown to be implicated in DNA damage response and 
DNA repair machineries [16, 17]. The rs585809 variant, 
which was mapped to the TRIM29 gene, was found to 
interact with CAGexp, suggesting that it might have an 
effect on AO through this interaction. Both RAG and 
TRIM29 loci were identified as AO-hastening 
modifiers. TRIM29 encodes for tripartite motif protein 
29, which is implicated in mismatch repair and double 
strand breaks pathways [18, 19]. TRIM29 is involved 
both upstream and downstream of these pathways, in 
the regulation of DNA repair proteins into chromatin by 
mediating the interaction between them. One of these 
DNA repair proteins is MLH1, which is implicated in 
mismatch repair complex [19]. Previously, the MLH1 
locus was identified as an AO modifier in another 
neurodegenerative disease caused by CAG repeat 
expansion, Huntington’s disease [9, 10, 20]. 
Additionally, in a genome-wide genetic screening 
study, MLH1-knock out was shown to modify  
the somatic expansion of the CAG repeat and slow the 




Figure 3. Visualization of the gene-sets and pathways enriched in primary GSEA analysis (A) and replicated in VEGAS and PASCAL 
(B). The size of the nodes corresponds to the number of the genes associated with a term. The significance is represented by the color 
of the nodes (P < 0.05, 0.05 < P < 0.1 and P > 0.1 are represented by red, yellow and gray, respectively).  
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Overall, the association of TRIM29 and RAG loci 
suggests that DNA repair mechanisms may be 
implicated in the alteration of AO of MJD, as well as 
HD, and may have a role in the pathogenesis of other 
CAG repeat diseases. Interestingly, in a previous study, 
we found variants in three transcription-coupled repair 
genes (ERCC6, RPA, and CDK7) associated with 
different CAG instability patterns in MJD [22]. 
 
We identified gene-sets enriched in olfactory 
signaling, vesicle transport, and synaptic pathways. 
Olfactory dysfunction is one of the main non-motor 
symptoms that was already described in patients with 
MJD [23, 24]. In a previous study, transplantation of 
olfactory ensheathing cells, which are specialized 
glial cells of the primary olfactory system, were found 
to improve motor function in an MJD mice model, 
and were suggested as a novel potential strategy for 
MJD treatment [25]. Vesicle transport and synaptic 
pathways were also implicated in MJD, as well as in 
other neurodegenerative diseases [26, 27]. An 
interruption of synaptic transmission caused by an 
expanded polyglutamine repeat and mutant ataxin-3 
aggregates were shown in Drosophila and 
Caenorhabditis elegans models of MJD. Therefore, 
the interaction between synaptic vesicles and mutant 
aggregates supports the role of synaptic vesicle 
transport in the pathogenesis of MJD [28, 29]. 
Overall, we suggest that these gene-sets and pathways 
might construct a larger molecular network that could 
modulate the AO in MJD. 
 
In summary, our study identified nine genetic loci that 
may modify the AO of MJD. Identification of TRIM29 
and RAG genetic variants, as well as our gene-set 
enrichment analyses, implicated DNA repair, olfactory 
signaling, synaptic, and vesicle transport pathways in 
the pathogenesis of MJD. Although we used different 
cohorts from five distinct geographical ethnicities, a 
replication study in similar or additional populations 
would add valuable evidence to support our findings. 
 




A total of 786 MJD patients from five distinct 
geographical origins (Portugal, Brazil, North 
America, Germany and Australia) were included in 
the present study. The overall average age at onset 
(standard deviation) was 38 (± 1.82) years, with a 1:1 
male to female ratio. All subjects provided informed 
consent, and the study was approved by the  
respective institutional review boards. Detailed  
cohort demographics are shown in Supplementary 
Table 2. 
Assessment of the ATXN3 CAG repeat length 
 
A singleplex polymerase chain reaction was performed to 
determine the length of the CAGexp and CAGnor alleles at 
exon 10 of ATXN3 [30]. The final volume for each assay 
was 10 µL: 7.5 ng of gDNA, 0.2 µM of each primer, 5 µL 
of Taq PCR Master Mix Kit Qiagen®, 1 µL of Q-Solution 
from Qiagen® and H2O. Fragment length analysis was 
done using ABIPrism 3730xl sequencer (Applied 
Biosystems®, McGill University and Genome Québec 
Innovation Centre) and GeneMapper software [31]. A 
stepwise regression model was performed to assess the 
correlation between AO and CAGexp size, as well as 
gender, origin, CAGnor size, and interaction between these 
variables. Residual AO was calculated for each subject by 
subtracting individual’s expected AO based upon CAGexp 
size from actual AO, to be used as the primary phenotype 
for following genetic approach. 
 
Genotyping, quality control and imputation 
 
Samples were genotyped using the Global Screening 
Array v.1.0 from Illumina (636,139 markers). Sample-
based (missingness, relatedness, sex, and multi-
dimensional scaling analysis) and SNP-based quality 
assessments (missingness, Hardy-Weinberg equilibrium, 
and minor allele frequency) were conducted using PLINK 
version 1.9 [32]. In sample level QC, samples were 
excluded with one or more of the following: high 
missingness (missingness rate > 0.05), close relationship 
(pi-hat value > 0.2), discrepancy between genetically-
inferred sex and reported sex, population outliers 
(deviation ≥ 4 SD from the population mean in 
multidimensional scaling analysis). All SNPs were 
checked for marker genotyping call rate (> 98%), minor 
allele frequency (MAF) > 0.05, and HWE (p-value 
threshold = 1.0 × 10-5).  
 
Phasing and imputation were performed using 
SHAPEIT [33] and PBWT [34] pipelines, implemented 
on the Sanger Imputation Service [35]. Haplotype 
Reference Consortium (HRC) reference panel r1.1 
containing 64,940 human haplotypes at 40,405,505 
genetic markers were used as the reference panel. 
Imputed variants with an allele count of 30 (MAF > 
0.02), an imputation quality score above 0.3 and an 
HWE p-value of > 1.0 × 10-5 were included for 
subsequent analysis.  
 
Genome-wide association analysis 
 
A genome-wide linear mixed model based association 
analysis was conducted using –mlma-loco option of 
GCTA version 1.91.7 [36]. Residual AO was 
modelled as a function of minor allele count of the 
test SNP, sex, and the first three principal components 
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based on the scree plot (Supplementary Figure 1). 
Manhattan plots were generated in FUMA v.1.3.4 
[37]. Regional association plots were generated using 
LocusZoom [38] (Supplementary Figure 2). 
 
Functional annotation of SNPs 
 
Genomic risk loci were defined using SNP2GENE 
function implemented in FUMA. Independent suggestive 
SNPs (P < 1 × 10−5) with a threshold of r2 < 0.6 were 
selected within a 250 kb window. The UK Biobank 
release 2 European population consisting of randomly 
selected 10,000 subjects was used as the reference 
population panel. The ANNOVAR [39] categories and 
combined annotation-dependent depletion (CADD) [40] 
scores were obtained from FUMA for functional 
annotation. Functionally annotated variants were mapped 
to genes based on genomic position using FUMA 




To identify known biological pathways and gene sets at 
the associated loci, an enrichment approach was applied 
using public datasets containing Gene Ontology (GO, 
http://geneontology.org), the Kyoto Encyclopaedia of 
Genes and Genomes (KEGG, https://www.genome. 
jp/kegg) and Reactome (https://reactome.org) pathways. 
The primary enrichment analysis was performed using 
the i-GSEA4GWAS v2. It uses a candidate list of a 
genome-wide set of genes mapped within the SNP loci 
and ranks them based on the strength of their 
association with the phenotype. Genes were mapped 
within 20 kb up or downstream of the SNPs with a 
P < 0.05. Gene and pathway sets meeting a false 
discovery rate (FDR)-corrected q-value < 0.05 were 
regarded as significantly associated with high 
confidence, and q-value < 0.25 was regarded to be 
possibly associated with the phenotype of interest. We 
performed a secondary gene-based association test 
using the Versatile Gene-based Association Study 
(VEGAS) algorithm that controls the number of SNPs 
in each gene and the linkage disequilibrium (LD) 
between these SNPs using the HapMap European 
population. As a third algorithm to identify enriched 
pathways, we used Pathway Scoring Algorithm 
(PASCAL), which controls for potential bias from gene 
size, SNP density, as well as LD. ClueGO [41] and 
CluePedia [42] plug-ins in Cytoscape were employed to 
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Supplementary Figure 1. Scree plot showing the eigenvalues of the first 20 principal components (PCs). This plot indicates that 
the first three PCs explain the majority of the variability in data. 
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Supplementary Figure 2. Regional LocusZoom plots for the nine modifier loci that modify AO of MJD. Purple line indicates the 
genetic recombination rate (cM/Mb). SNPs in linkage disequilibrium with identified are shown in color gradient indicating r2 levels (hg19, 
1KGP, Nov 2014, EUR). 
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Supplementary Tables 
 
Supplementary Table 1. Linear relationship between AO and CAGexp, CAGnor, geographical origin, sex and pairwise 
interaction of the given factors. A total of 62.7 % of the variability in the AO is explained by given factors. 
Model description Multiple R2 Adjusted R2 P-value ΔR2 
AO ~ CAGexp 0.6200 0.6195 <2.2 × 10−16 
 
AO ~ CAGexp + origin 0.6241 0.6216 <2.2 × 10−16 0.0021 
AO ~ CAGexp + origin + sex 0.6265 0.6235 <2.2 × 10−16 0.0019 
AO ~ CAGexp + origin + sex + CAGnor 0.6282 0.6247 <2.2 × 10−16 0.0012 
AO ~ CAGexp + origin + sex + CAGnor + CAGexp:CAGnor 0.6301 0.6261 <2.2 × 10−16 0.0014 
AO ~ CAGexp + origin + sex + CAGnor + CAGexp:CAGnor 
+ CAGexp:origin 
0.6328 0.6267 <2.2 × 10−16 0.0006 
AO ~ CAGexp + origin + sex + CAGnor + CAGexp:CAGnor 
+ CAGexp:origin + CAGnor:origin 
0.6352 0.6271 <2.2 × 10−16 0.0004 
 
Supplementary Table 2. Subjects and cohort demographics. 
Geographical origin # of patients Mean (SD) AO M:F 
Portugal 330 40.0 (±12.4) 1.0 
Brazil 311 34.9 (±11.7) 1.1 
North America 55 37.8 (±12.2) 0.7 
Germany 51 37.6 (±9.2) 1.2 
NA 34 37.1 (±11.1) 1.4 
Australia 5 52.8 (±10.1) 0.3 
M:F - male-female ratio. 
 
Please browse Full Text version to see the data of Supplementary Tables 3 and 4. 
 
Supplementary Table 3. Functional annotation of SNPs. rsID: reference SNP ID; MAF: minor alelle frequency; r2: the 
maximum r2 of the SNP with one of the independent significant SNPs; nearest gene: the nearest Gene of the SNP based 
on ANNOVAR annotations; distance: distance to the nearest gene; func: functional consequence of the SNP on the 
gene obtained from ANNOVAR; CADD: CADD score which is computed based on 63 annotations. 
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Supplementary Table 5. Gene sets and pathways enriched in i-GSEA4GWAS. 
Pathway/Gene set name Gene Set ID P-value FDR 
GO: TRANSPORT VESICLE  GO:0030133 0.001 0.0082 
KEGG: OLFACTORY TRANSDUCTION  hsa04740 0.001 0.0083 
Olfactory Signaling Pathway  R-HSA-381753 0.001 0.0088 
GO: SYNAPSE PART  GO:0044456 0.001 0.0093 
Synthesis of bile acids and bile salts via 24-hydroxycholesterol  R-HSA-193775 0.001 0.0095 
Negative feedback regulation of MAPK pathway  R-HSA-5674499 0.001 0.0101 
Purine salvage  R-HSA-74217 0.001 0.0106 
GO: METALLOEXOPEPTIDASE ACTIVITY  GO:0008235 0.001 0.0109 
GO: SYNAPSE  GO:0045202 0.001 0.0115 
GO: MONOCARBOXYLIC ACID TRANSPORT  GO:0015718 0.001 0.0133 
GO: OUTER MEMBRANE  GO:0019867 0.001 0.0141 
GO: AMINOPEPTIDASE ACTIVITY  GO:0004177 0.001 0.015 
Localization of the PINCH-ILK-PARVIN complex to focal adhesions  R-HSA-446343 0.001 0.0159 
BioCarta: PLATELETAPP PATHWAY  M6487 0.001 0.0161 
GO: EXOPEPTIDASE ACTIVITY  GO:0008238 0.001 0.018 
TFAP2 (AP-2) family regulates transcription of other transcription factors  R-HSA-8866906 0.001 0.0212 
GO: MITOCHONDRIAL OUTER MEMBRANE  GO:0005741 0.001 0.0215 
GO: ORGANELLE OUTER MEMBRANE  GO:0031968 0.003 0.0216 
GO: HISTONE DEACETYLASE COMPLEX  GO:0000118 0.001 0.0218 
Fanconi Anemia Pathway  R-HSA-6783310 0.001 0.0221 
GO: PROTEASOME COMPLEX  GO:0000502 0.001 0.0221 
GO: RECEPTOR MEDIATED ENDOCYTOSIS  GO:0006898 0.001 0.0225 
GO: GABA RECEPTOR ACTIVITY  GO:0016917 0.001 0.0226 
Metabolism of Angiotensinogen to Angiotensins  R-HSA-2022377 0.001 0.0231 
GO: TRANS GOLGI NETWORK TRANSPORT VESICLE  GO:0030140 0.001 0.0236 
Calcitonin-like ligand receptors  R-HSA-419812 0.001 0.0242 
GO: MONOCARBOXYLIC ACID TRANSMEMBRANE 
TRANSPORTER ACTIVITY 
GO:0008028. 0.001 0.0245 
HDL remodeling  R-HSA-8964058 0.001 0.0262 
Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)  R-HSA-2142670 0.001 0.0263 
GO: RESPONSE TO HORMONE STIMULUS  GO:0009725 0.001 0.0273 
GO: PEPTIDE METABOLIC PROCESS  GO:0006518 0.004 0.0348 
GRB7 events in ERBB2 signaling  R-HSA-1306955 0.001 0.0348 
Mitochondrial Uncoupling Proteins  R-HSA-166187 0.008 0.0354 
The fatty acid cycling model  R-HSA-167826 0.008 0.0354 
The proton buffering model  R-HSA-167827 0.008 0.0354 
ATF6 (ATF6-alpha) activates chaperone genes  R-HSA-381183 0.002 0.037 
GO: GOLGI ASSOCIATED VESICLE  GO:0005798 0.003 0.0371 
Free fatty acids regulate insulin secretion  R-HSA-400451 0.001 0.0374 
GO: XENOBIOTIC METABOLIC PROCESS  GO:0006805 0.001 0.0382 
GO: DENDRITE  GO:0030425 0.001 0.0386 
Beta-oxidation of pristanoyl-CoA  R-HSA-389887 0.001 0.0413 
Toxicity of botulinum toxin type D (BoNT/D)  R-HSA-5250955 0.001 0.0414 
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Toxicity of botulinum toxin type F (BoNT/F)  R-HSA-5250981 0.001 0.0414 
Processing and activation of SUMO  R-HSA-3215018 0.001 0.0416 
KEGG: NUCLEOTIDE EXCISION REPAIR  hsa03420 0.001 0.0422 
GO: RESPONSE TO XENOBIOTIC STIMULUS  GO:0009410 0.001 0.0462 
 
Please browse Full Text version to see the data of Supplementary Tables 6, 7. 
 
Supplementary Table 6. Gene sets and pathways enriched in i-GSEA4GWAS. 
Supplementary Table 7. Top gene sets and pathways enriched in PASCAL. 
 
